摘要
目的评价缬沙坦治疗轻、中度老年原发性高血压的临床疗效及安全性。方法将170例轻、中度老年原发性高血压患者随机分为观察组与对照组，观察组用缬沙坦80～160mg／d治疗，对照组用贝那普利10～20mg／d治疗，为期12周。结果两组总有效率、降压幅度分别为79％和78％、31／22mmHg和32／23mmHg，两组间比较无显著性差异（P〉0．05）；两组均能较明显改善左心室心肌肥厚（均P〈0．05），但两组间对比无显著性差异（P〉0．05）；不良反应两组都轻，但观察组明显少于对照组（P〈0．05）。结论缬沙坦治疗轻、中度老年原发性高血压疗效好、安全性高，可作为轻、中度老年原发性高血压患者降压首选药物之一。
Objective To evaluate the clinical effects and safety of treating mide to moderate senile primary hypertension with valsartan. Methods One hundred and seventy cases were assigned into two groups, one were treated with valsartan 80 - 160 mg（group of observation） ,another with benazepril 10 -20 mg（group of control）once daily for 12 week. Results The total effective rate, amplitude of blood pressure reducde in valsartan and benazepril group were 79% and 78% ,31/22 mm Hg and 32/23 mm Hg, and no significant differences existed between two groups（P 〉0. 05 ）. Left ventriculr hypertrophy was obviously improved in both groups （P 〈 0. 05 ）, but there were no significant differences between two groups （P 〉 0. 05 ）. Adverse reactions were mild in both groups,but were less in valsartan group （P 〈 0. 05 ）. Conclusion Valsartan is a good clinical effective and safe drug. It may be one of drugs setecled at first for treating mide to moderate senile primary hypertension.
出处
《中国医学创新》
CAS
2009年第15期15-16,共2页
Medical Innovation of China
